Related MeSH Hierarchy (7)
Diseases [C] » Otorhinolaryngologic Diseases [C09] » Otorhinolaryngologic Neoplasms » Pharyngeal Neoplasms » Nasopharyngeal Neoplasms » Nasopharyngeal Carcinoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Nasopharyngeal Carcinoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Head and Neck Neoplasms » Otorhinolaryngologic Neoplasms » Pharyngeal Neoplasms » Nasopharyngeal Neoplasms » Nasopharyngeal Carcinoma
Diseases [C] » Stomatognathic Diseases [C07] » Pharyngeal Diseases » Nasopharyngeal Diseases » Nasopharyngeal Neoplasms » Nasopharyngeal Carcinoma
Diseases [C] » Stomatognathic Diseases [C07] » Pharyngeal Diseases » Pharyngeal Neoplasms » Nasopharyngeal Neoplasms » Nasopharyngeal Carcinoma
Diseases [C] » Otorhinolaryngologic Diseases [C09] » Pharyngeal Diseases » Nasopharyngeal Diseases » Nasopharyngeal Neoplasms » Nasopharyngeal Carcinoma
Diseases [C] » Otorhinolaryngologic Diseases [C09] » Pharyngeal Diseases » Pharyngeal Neoplasms » Nasopharyngeal Neoplasms » Nasopharyngeal Carcinoma
Description
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes. MeSH
Hierarchy View
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (3)
Phase 3 Indicated Drugs (31)
Phase 1 Indicated Drugs (28)
Other Experimental Indicated Drugs (9)
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (81)
Bureau of Science and Technology of Guangxi Province, China
Cancer Hospital of Guizhou Province
Chinese Southwest Oncology Group
Chinese University of Hong Kong
First People's Hospital of Foshan
First People's Hospital of Yulin
Hong Kong Nasopharyngeal Cancer Study Group Limited
Huazhong University of Science and Technology
Innovent Biologics (Suzhou) Co. Ltd.
Jiangsu Cancer Institute & Hospital
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Jiangxi Provincial Cancer Hospital
Meizhou City Hospital Of Guangdong Provience
Nanning Second People's Hospital
National Cancer Institute (NCI)
National Cheng Kung University
Ningbo Medical Center Lihuili Eastern Hospital
People's Hospital of Zhongshan
Organization Involved with Phase 2 Indications (81)
Betta Pharmaceuticals Co.,Ltd.
Case Western Reserve University
Department of Radiation Oncology
Eastern Cooperative Oncology Group
Guilin Hospital of Traditional Chinese Medicine
Methodist Cancer Center, Houston, Texas
National Comprehensive Cancer Network
Radiation Therapy Oncology Group
Shanghai Junshi Bioscience Co.,Ltd.
Shenzhen Hank Bioengineering Institute
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Simcere Pharmaceutical Co., Ltd
Organization Involved with Phase 1 Indications (19)
Organization Involved with Other Experimental Indications (5)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
